The carcinogenic changes of RET have been found in a variety of tumor types, including 1-2% of non-small cell lung cancer (NSCLC)
We aim to evaluate the safety, tolerability and anti-tumor activity of Palaxitinib.
Palaxitinib is a potent oral selective RET inhibitor for patients with RET fusion-positive NSCLC
The purpose of this study was to evaluate the safety, tolerability and anti-tumor activity of pratinib (Pralsetinib, a highly effective, oral, and selective RET inhibitor) in patients with RET fusion-positive NSCLC
The ARROW trial is a multi-cohort, open-label Phase 1/2 study conducted at 71 locations in 12 countries, recruiting patients with locally advanced or metastatic solid tumors over 18 years of age, including NSCLC with RET fusion-positive NSCLC Patient
Include patients with locally advanced or metastatic solid tumors 18 years of age or older, including RET fusion-positive NSCLC, and the performance status of the Eastern Cooperative Oncology Group 0-2 (later restricted to 0- in the protocol revision 1) In the second phase, the patient is treated with 400 mg of pratinib orally every day until the disease progresses, intolerance, withdrawal from the trial or the investigator's decision
The primary endpoint is the overall response rate (according to the version 1.
1 of the solid tumor response evaluation standard and evaluated by a blinded independent center review) and safety
To evaluate the tumor response of RET fusion-positive NSCLC patients.
Leave a message here